NO20060651L - Fremgangsmate for behandling av virale infeksjoner - Google Patents

Fremgangsmate for behandling av virale infeksjoner

Info

Publication number
NO20060651L
NO20060651L NO20060651A NO20060651A NO20060651L NO 20060651 L NO20060651 L NO 20060651L NO 20060651 A NO20060651 A NO 20060651A NO 20060651 A NO20060651 A NO 20060651A NO 20060651 L NO20060651 L NO 20060651L
Authority
NO
Norway
Prior art keywords
ribavirin
interferon
related compound
administering
day
Prior art date
Application number
NO20060651A
Other languages
English (en)
Inventor
Howard J Smith
Original Assignee
Smith Howard J & Ass Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060651(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smith Howard J & Ass Pty Ltd filed Critical Smith Howard J & Ass Pty Ltd
Publication of NO20060651L publication Critical patent/NO20060651L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåte for farmasøytisk behandling omfattende koadministrering av hvilken som helst form av interferon eller hvilket som helst derivat derav med en lav dose av ribavirin (mindre enn 400 mg/dag eller mindre enn 6 mg/kgldag), eller relatert forbindelse, hvor ribavirin eller relatert forbindelse tilveiebringer et klinisk effektivt blodnivå i portalsirkulasjonen men et lavere enn klinisk effektivt blodnivå i den perifere sirkulasjonen, for derved å tilveiebringe en systemisk effekt av interferon gjennom hele kroppen men en selektiv effekt av ribavirin i leveren. Fremgangsmåten omfatter også koadministrering av hvilken som helst form av interferon eller hvilket som helst derivat derav med en høy dose av ribavirin (foretrukket fra 400-800 mg/dag), eller relatert forbindelse, hvor ribavirin eller reltert forbindelse administreres som en formulering med langsom frigjøring slik at den også tilveiebringer en vedvarende virologisk respons hos en pasient og reduserte bivirkninger. Fremgangsmåten omfatter også koadministrering av en oksidant eller annet middel som beskytter membraner med både interferonet og ribavirinet slik at den hepatoprotektive aktiviteten av antioksidanten eller annet middel som beskytter membraner komplementarer vimcid effekten av interferonet og ribavirinet. Antioksidanten eller annet middel som beskytter membraner kan administreres som en systemisk eller lavdose, slow-release leverselektiv formulering.
NO20060651A 2003-08-13 2006-02-09 Fremgangsmate for behandling av virale infeksjoner NO20060651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49482803P 2003-08-13 2003-08-13
PCT/AU2004/001031 WO2005016370A1 (en) 2003-08-13 2004-08-03 Method of treating viral infections

Publications (1)

Publication Number Publication Date
NO20060651L true NO20060651L (no) 2006-05-02

Family

ID=34193246

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060651A NO20060651L (no) 2003-08-13 2006-02-09 Fremgangsmate for behandling av virale infeksjoner

Country Status (15)

Country Link
US (1) US20070202078A1 (no)
EP (1) EP1660116A4 (no)
JP (1) JP2007501806A (no)
CN (1) CN1835765A (no)
AR (1) AR045263A1 (no)
AU (1) AU2004264255A1 (no)
BR (1) BRPI0413474A (no)
CA (1) CA2535451A1 (no)
CL (1) CL2004002030A1 (no)
IL (1) IL173630A0 (no)
NO (1) NO20060651L (no)
NZ (1) NZ545159A (no)
RU (1) RU2371195C2 (no)
WO (1) WO2005016370A1 (no)
ZA (1) ZA200601181B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
CN1847256B (zh) * 2005-04-13 2011-06-15 长春华普生物技术有限公司 含CpG单链脱氧寡核苷酸和利巴韦林联合应用产生的抗病毒作用
WO2006131790A2 (en) * 2005-06-09 2006-12-14 Flamel Technologies Oral ribavirin pharmaceutical composition
CN105521485A (zh) * 2007-09-05 2016-04-27 尼古拉·叶夫根尼耶维奇·沙图诺夫斯基 脱铁乳铁蛋白组合物及其用于治疗病毒性丙型肝炎的方法
US20110270212A1 (en) * 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery
BRPI0918653A2 (pt) * 2008-09-17 2015-12-01 Boehringer Ingelheim Int combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
EP2364098B1 (en) * 2008-12-16 2016-10-12 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
WO2011053617A1 (en) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
SG190357A1 (en) 2010-11-19 2013-06-28 Venus Remedies Ltd Novel conjugates for targeted drug delivery
RU2665638C1 (ru) * 2017-05-24 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3222259A (en) * 1963-10-25 1965-12-07 Ethyl Corp Flare stack with a liquid seal
JPS5439143Y2 (no) * 1976-04-16 1979-11-20
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DE69801970T2 (de) * 1997-09-21 2002-06-13 Schering Corp., Kenilworth Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
JP5281726B2 (ja) * 1998-05-15 2013-09-04 メルク・シャープ・アンド・ドーム・コーポレーション 慢性Ｃ型肝炎感染を有する、抗ウイルス処置を受けていない患者における、リバビリンおよびインターフェロンαを含む併用療法
NZ510811A (en) * 1998-10-16 2003-06-30 Schering Corp Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
WO2000037110A2 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
CN1355708A (zh) * 1999-04-19 2002-06-26 先灵公司 包含利巴韦林与抗氧化剂的hcv联合治疗
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CN1516599A (zh) * 2000-10-18 2004-07-28 ���鹫˾ 病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
US6544497B2 (en) * 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
PL369129A1 (en) * 2001-09-28 2005-04-18 Intermune, Inc. Method for treating hepatitis c virus infection in treatment failure patients
CA2372987A1 (en) * 2001-12-11 2003-06-11 Thomas R. Wiseman Method of disposal of liquid from gas wells

Also Published As

Publication number Publication date
CN1835765A (zh) 2006-09-20
WO2005016370A1 (en) 2005-02-24
US20070202078A1 (en) 2007-08-30
EP1660116A1 (en) 2006-05-31
RU2006107566A (ru) 2007-09-20
AR045263A1 (es) 2005-10-19
RU2371195C2 (ru) 2009-10-27
ZA200601181B (en) 2007-04-25
NZ545159A (en) 2009-03-31
EP1660116A4 (en) 2008-04-30
CL2004002030A1 (es) 2005-06-03
BRPI0413474A (pt) 2006-10-17
JP2007501806A (ja) 2007-02-01
CA2535451A1 (en) 2005-02-24
IL173630A0 (en) 2006-07-05
AU2004264255A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
NO20060651L (no) Fremgangsmate for behandling av virale infeksjoner
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
EP2219642B1 (en) Silibinin component for the treatment of hepatitis
ES2324909T3 (es) Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion.
JP2005289996A5 (no)
HUP0001382A2 (hu) Eritromicinszármazékokat tartalmazó, ezek késleltetett felszabadulását biztosító készítmények
MY143795A (en) Tetrahydropyridoindole derivatives
BR0316082A (pt) Métodos de tratar ou prevenir e de controlar uma doença mieloproliferative, de reduzir ou evitar um efeito adverso associado com a administração de um segundo agente ativo em um paciente sofrendo de uma doença mieloproliferativa e de aumentar a eficácia terapêutica de um tratamento de doenças mieloproliferativa, composição farmacêutica e kit
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
JP2003506416A5 (no)
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
MXPA05005046A (es) Formulaciones parasiticidas topicas y metodos de tratamiento.
RU2366450C1 (ru) Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
BR0315316A (pt) Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
JP2006511538A5 (no)
ATE533509T1 (de) Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
WO2004041190A3 (en) Composition for the treatment of macular degenration
US20170312297A1 (en) Long Acting Pharmaceutical Compositions For Hepatitis C
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
AU5158000A (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
DK1212050T3 (da) Formuleringer indeholdende tetracycliner til behandling eller forebyggelse af mucositis
WO2001045727A3 (en) Stabilized veterinary compositions comprising more than one antiviral agent
JP2017514834A5 (no)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application